| Schedule of Segment Reporting Information, by Segment [Table Text Block] |
| |
|
Quarter Ended |
|
|
Nine Months Ended |
|
| |
|
March 31, |
|
|
March 31, |
|
| |
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
| Net sales: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Protein Sciences |
|
$ |
145,509 |
|
|
$ |
137,935 |
|
|
$ |
428,021 |
|
|
$ |
399,787 |
|
| Diagnostics and Genomics |
|
|
49,411 |
|
|
|
47,134 |
|
|
|
135,808 |
|
|
|
123,144 |
|
| Intersegment |
|
|
(240 |
) |
|
|
(208 |
) |
|
|
(972 |
) |
|
|
(590 |
) |
| Consolidated net sales |
|
$ |
194,680 |
|
|
$ |
184,861 |
|
|
$ |
562,857 |
|
|
$ |
522,341 |
|
| Operating income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Protein Sciences |
|
$ |
65,046 |
|
|
$ |
62,256 |
|
|
$ |
185,456 |
|
|
$ |
175,821 |
|
| Diagnostics and Genomics |
|
|
7,062 |
|
|
|
3,579 |
|
|
|
8,937 |
|
|
|
5,061 |
|
| Segment operating income |
|
$ |
72,108 |
|
|
$ |
65,835 |
|
|
$ |
194,393 |
|
|
$ |
180,882 |
|
| Costs recognized on sale of acquired inventory |
|
|
- |
|
|
|
(935 |
) |
|
|
- |
|
|
|
(2,804 |
) |
| Amortization of acquisition related intangible assets |
|
|
(15,459 |
) |
|
|
(14,400 |
) |
|
|
(45,467 |
) |
|
|
(43,678 |
) |
| Acquisition related expenses |
|
|
322 |
|
|
|
- |
|
|
|
(107 |
) |
|
|
(2,973 |
) |
| Stock based compensation |
|
|
(8,088 |
) |
|
|
(5,725 |
) |
|
|
(27,505 |
) |
|
|
(24,151 |
) |
| Corporate general, selling, and administrative expenses |
|
|
(1,092 |
) |
|
|
(685 |
) |
|
|
(3,205 |
) |
|
|
(3,821 |
) |
| Consolidated operating income |
|
$ |
47,791 |
|
|
$ |
44,090 |
|
|
$ |
118,109 |
|
|
$ |
103,455 |
|
|